InfoBionic Secures Series D Funding to Catalyze Growth of its Virtual Telemetry Solution

InfoBionic, a digital health company focused on virtual telemetry and cardiac remote patient monitoring, has closed a Series D financing round to support continued domestic growth and international expansion of its U.S. Food and Drug Administration (FDA) approved  MoMe ARC system for virtual telemetry and remote wireless monitoring and detection of cardiac arrhythmias. The funding round included participation by Security International Investments (SII), Mayo Clinic and Excel Venture Management while existing investors Blue Cross Blue Shield of MA (Zaffre Investments), Blue Cross Blue Shield of Kansas, and Safeguard Scientifics remain actively involved. 

“We’re very proud of our role in the evolving transformation of virtual telemetry for remote cardiac monitoring and we are excited at the prospects of what we can accomplish in this next phase of virtual care,” InfoBionic CEO Stuart Long said. “We are pleased by the completion of this latest round which was based on the strong market traction of our proprietary MoMe® Kardia system. Through collaborations with great minds in medicine and technology we remain committed to doing things better to improve patient outcomes while making it easier and more efficient for the many providers that care for those patients.” 
 
The company’s flagship product—the MoMe ARC four-in-one monitor, its third generation remote ECG monitoring device paired with its inaugural Bluetooth diagnostic six-lead sensor—is designed to help physicians diagnose cardiac arrhythmias in patients with a demonstrated need for cardiac monitoring. Now delivering both the convenience of a patch-type sensor and quality of a wire-based system, InfoBionic has been recognized as the gold standard in remote ECG quality with its capability to offer true full disclosure, heartbeat-to-heartbeat data over the Cloud, allowing doctors 24/7 near real-time access to hospital telemetry-level data, and rapid diagnosis. MoMe ARC is not intended for use as an emergency medical response system.
 
InfoBionic’s digital technology has transformed the efficiency and economics of cardiac remote patient monitoring. The company’s vision for its recently FDA approved third-generation platform MoMe ARC platform is to remove the roadblocks hindering virtual and remote diagnosis and decision-making. The Massachusetts-based team of entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology and bring specific expertise in remote monitoring and cardiology.